281 related articles for article (PubMed ID: 24638984)
21. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
Faivre S; Santoro A; Kelley RK; Gane E; Costentin CE; Gueorguieva I; Smith C; Cleverly A; Lahn MM; Raymond E; Benhadji KA; Giannelli G
Liver Int; 2019 Aug; 39(8):1468-1477. PubMed ID: 30963691
[TBL] [Abstract][Full Text] [Related]
22. Hypotheses on the role of transforming growth factor-beta in the onset and progression of hepatocellular carcinoma.
Dooley S; Weng H; Mertens PR
Dig Dis; 2009; 27(2):93-101. PubMed ID: 19546546
[TBL] [Abstract][Full Text] [Related]
23. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
Dituri F; Mazzocca A; Fernando J; Peidrò FJ; Papappicco P; Fabregat I; De Santis F; Paradiso A; Sabbà C; Giannelli G
PLoS One; 2013; 8(6):e67109. PubMed ID: 23826206
[TBL] [Abstract][Full Text] [Related]
24. PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression.
Fischer AN; Fuchs E; Mikula M; Huber H; Beug H; Mikulits W
Oncogene; 2007 May; 26(23):3395-405. PubMed ID: 17130832
[TBL] [Abstract][Full Text] [Related]
25. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
Giannelli G; Santoro A; Kelley RK; Gane E; Paradis V; Cleverly A; Smith C; Estrem ST; Man M; Wang S; Lahn MM; Raymond E; Benhadji KA; Faivre S
PLoS One; 2020; 15(3):e0222259. PubMed ID: 32210440
[TBL] [Abstract][Full Text] [Related]
26. Dysregulation of apoptosis in hepatocellular carcinoma.
Thorgeirsson SS; Teramoto T; Factor VM
Semin Liver Dis; 1998; 18(2):115-22. PubMed ID: 9606809
[TBL] [Abstract][Full Text] [Related]
27. Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling.
Zhang Q; Bai X; Chen W; Ma T; Hu Q; Liang C; Xie S; Chen C; Hu L; Xu S; Liang T
Carcinogenesis; 2013 May; 34(5):962-73. PubMed ID: 23358852
[TBL] [Abstract][Full Text] [Related]
28. Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells.
Saito RA; Watabe T; Horiguchi K; Kohyama T; Saitoh M; Nagase T; Miyazono K
Cancer Res; 2009 Apr; 69(7):2783-91. PubMed ID: 19293183
[TBL] [Abstract][Full Text] [Related]
29. Transforming Growth Factor-β Promotes Morphomechanical Effects Involved in Epithelial to Mesenchymal Transition in Living Hepatocellular Carcinoma.
Cascione M; Leporatti S; Dituri F; Giannelli G
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30597907
[TBL] [Abstract][Full Text] [Related]
30. A TGFβ Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGFβ-independent Manner.
Ishigami I; Shuwari N; Kaminade T; Mizuguchi H; Sakurai F
Anticancer Res; 2021 May; 41(5):2431-2440. PubMed ID: 33952468
[TBL] [Abstract][Full Text] [Related]
31. Biology of transforming growth factor beta in hepatocarcinogenesis.
Rossmanith W; Schulte-Hermann R
Microsc Res Tech; 2001 Feb; 52(4):430-6. PubMed ID: 11170302
[TBL] [Abstract][Full Text] [Related]
32. TGF-β as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives.
Dituri F; Mancarella S; Cigliano A; Chieti A; Giannelli G
Semin Liver Dis; 2019 Feb; 39(1):53-69. PubMed ID: 30586675
[TBL] [Abstract][Full Text] [Related]
33. Dissecting the effect of targeting the epidermal growth factor receptor on TGF-β-induced-apoptosis in human hepatocellular carcinoma cells.
Caja L; Sancho P; Bertran E; Fabregat I
J Hepatol; 2011 Aug; 55(2):351-8. PubMed ID: 21147185
[TBL] [Abstract][Full Text] [Related]
34. The TGF-β signaling pathway as a pharmacological target in a hepatocellular carcinoma.
Mazzocca A; Antonaci S; Giannelli G
Curr Pharm Des; 2012; 18(27):4148-54. PubMed ID: 22630081
[TBL] [Abstract][Full Text] [Related]
35. TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation.
Fuxe J; Karlsson MC
Semin Cancer Biol; 2012 Oct; 22(5-6):455-61. PubMed ID: 22627188
[TBL] [Abstract][Full Text] [Related]
36. Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model.
Hammad S; Cavalcanti E; Werle J; Caruso ML; Dropmann A; Ignazzi A; Ebert MP; Dooley S; Giannelli G
Arch Toxicol; 2018 Jul; 92(7):2297-2309. PubMed ID: 29808285
[TBL] [Abstract][Full Text] [Related]
37. Attenuation of transforming growth factor beta-induced growth inhibition in human hepatocellular carcinoma cell lines by cyclin D1 overexpression.
Jong HS; Lee HS; Kim TY; Im YH; Park JW; Kim NK; Bang YJ
Biochem Biophys Res Commun; 2002 Mar; 292(2):383-9. PubMed ID: 11906173
[TBL] [Abstract][Full Text] [Related]
38. Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth.
Senturk S; Mumcuoglu M; Gursoy-Yuzugullu O; Cingoz B; Akcali KC; Ozturk M
Hepatology; 2010 Sep; 52(3):966-74. PubMed ID: 20583212
[TBL] [Abstract][Full Text] [Related]
39. SCUBE3 is an endogenous TGF-β receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer.
Wu YY; Peck K; Chang YL; Pan SH; Cheng YF; Lin JC; Yang RB; Hong TM; Yang PC
Oncogene; 2011 Aug; 30(34):3682-93. PubMed ID: 21441952
[TBL] [Abstract][Full Text] [Related]
40. Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma.
Rimassa L; Personeni N; Simonelli M; Santoro A
Future Oncol; 2013 Feb; 9(2):153-65. PubMed ID: 23414466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
